Published in Proc Natl Acad Sci U S A on February 28, 2011
Genomics: ENCODE explained. Nature (2012) 2.62
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res (2011) 2.15
A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res (2012) 1.92
DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol (2013) 1.71
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res (2012) 1.63
Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biol (2012) 1.63
DNA methylation reprogramming in cancer: does it act by re-configuring the binding landscape of Polycomb repressive complexes? Bioessays (2013) 1.45
Epigenetics in breast cancer: what's new? Breast Cancer Res (2011) 1.36
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res (2012) 1.35
Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat (2011) 1.22
Genomic insights into cancer-associated aberrant CpG island hypermethylation. Brief Funct Genomics (2013) 1.11
Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics (2012) 1.08
COHCAP: an integrative genomic pipeline for single-nucleotide resolution DNA methylation analysis. Nucleic Acids Res (2013) 1.08
Identification of DNA methylation biomarkers from Infinium arrays. Front Genet (2012) 1.05
Molecular characterisation of cell line models for triple-negative breast cancers. BMC Genomics (2012) 1.03
Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer. Nucleic Acids Res (2013) 1.03
Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips. Epigenetics (2013) 1.02
Defending the genome from the enemy within: mechanisms of retrotransposon suppression in the mouse germline. Cell Mol Life Sci (2013) 0.97
DNA methylation, its mediators and genome integrity. Int J Biol Sci (2015) 0.96
Absence of Runx3 expression in normal gastrointestinal epithelium calls into question its tumour suppressor function. EMBO Mol Med (2011) 0.95
Expression of a large LINE-1-driven antisense RNA is linked to epigenetic silencing of the metastasis suppressor gene TFPI-2 in cancer. Nucleic Acids Res (2013) 0.91
NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A (2016) 0.91
Genomic interaction profiles in breast cancer reveal altered chromatin architecture. PLoS One (2013) 0.88
Lineage-specific RUNX3 hypomethylation marks the preneoplastic immune component of gastric cancer. Oncogene (2014) 0.88
Meta-analysis of human methylation data for evidence of sex-specific autosomal patterns. BMC Genomics (2014) 0.87
Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol Cancer Res (2011) 0.87
A novel reannotation strategy for dissecting DNA methylation patterns of human long intergenic non-coding RNAs in cancers. Nucleic Acids Res (2014) 0.87
Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer. Clin Epigenetics (2014) 0.86
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics (2014) 0.85
Changes in correlation between promoter methylation and gene expression in cancer. BMC Genomics (2015) 0.83
Cell-type specific DNA methylation patterns define human breast cellular identity. PLoS One (2012) 0.82
Immortality, but not oncogenic transformation, of primary human cells leads to epigenetic reprogramming of DNA methylation and gene expression. Nucleic Acids Res (2013) 0.81
Transcriptional repressor domain of MBD1 is intrinsically disordered and interacts with its binding partners in a selective manner. Sci Rep (2014) 0.79
Reprogramming cancer cells to pluripotency: an experimental tool for exploring cancer epigenetics. Epigenetics (2014) 0.79
Altered promoter nucleosome positioning is an early event in gene silencing. Epigenetics (2014) 0.79
Integrative modelling of tumour DNA methylation quantifies the contribution of metabolism. Nat Commun (2016) 0.77
Tissue-independent and tissue-specific patterns of DNA methylation alteration in cancer. Epigenetics Chromatin (2016) 0.77
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. PLoS One (2015) 0.77
Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome. Stem Cells Transl Med (2014) 0.76
An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells. Breast Cancer Res (2016) 0.76
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia (2015) 0.75
A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis. PLoS One (2016) 0.75
Distal CpG islands can serve as alternative promoters to transcribe genes with silenced proximal promoters. Genome Res (2017) 0.75
Multivariate Boosting for Integrative Analysis of High-Dimensional Cancer Genomic Data. Cancer Inform (2015) 0.75
The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics. PLoS One (2017) 0.75
RUNX3 methylation and anti-tumor immunity. Oncoscience (2015) 0.75
An annotated list of bivalent chromatin regions in human ES cells: a new tool for cancer epigenetic research. Oncotarget (2016) 0.75
Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1. Oncotarget (2016) 0.75
Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA). Medicine (Baltimore) (2017) 0.75
The DNA methylation landscape of human melanoma. Genomics (2015) 0.75
DNA methylation patterns and epigenetic memory. Genes Dev (2002) 33.83
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Generation of a functional mammary gland from a single stem cell. Nature (2006) 18.30
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88
Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet (2010) 10.71
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
A gene hypermethylation profile of human cancer. Cancer Res (2001) 8.93
Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell Stem Cell (2007) 7.05
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet (2006) 4.97
BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene (2006) 3.91
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res (2006) 3.59
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
DNA methylation and breast carcinogenesis. Oncogene (2002) 3.03
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res (2004) 2.82
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res (2003) 2.61
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A (2006) 2.25
DNA methylation is a primary mechanism for silencing postmigratory primordial germ cell genes in both germ cell and somatic cell lineages. Development (2006) 2.08
TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res (2000) 1.98
Methylation not a frequent "second hit" in tumors with germline BRCA mutations. Fam Cancer (2009) 1.78
Do 'basal-like' breast cancers really exist? Nat Rev Cancer (2008) 1.55
Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma. Cancer Genet Cytogenet (1997) 1.55
Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res (2004) 1.55
CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer (2006) 1.41
Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res (2010) 1.37
Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol (2008) 1.12
Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer (2009) 1.12
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res (2010) 0.97
Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype. Br J Cancer (2010) 0.93
Infiltrating leukocytes confound the detection of E-cadherin promoter methylation in tumors. Biochem Biophys Res Commun (2004) 0.91
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst (2006) 7.29
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst (2007) 4.46
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
Orphan CpG islands identify numerous conserved promoters in the mammalian genome. PLoS Genet (2010) 3.38
Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat (2005) 3.23
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol (2012) 3.16
Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol (2008) 3.06
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res (2005) 2.42
Consensus conference on breast conservation. J Am Coll Surg (2006) 2.17
Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res (2011) 2.15
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. J Clin Oncol (2005) 2.04
Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet (2002) 1.96
Genome-wide methylation profiling in Crohn's disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway. Inflamm Bowel Dis (2011) 1.88
Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer (2010) 1.85
De novo methylation of MMLV provirus in embryonic stem cells: CpG versus non-CpG methylation. Gene (2002) 1.80
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res (2010) 1.65
Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biol (2012) 1.63
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol (2006) 1.62
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res (2010) 1.62
A mutant form of MeCP2 protein associated with human Rett syndrome cannot be displaced from methylated DNA by notch in Xenopus embryos. Mol Cell (2003) 1.61
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat (2010) 1.59
Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res (2009) 1.59
Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol (2009) 1.58
The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care (2008) 1.56
Promoter DNA methylation couples genome-defence mechanisms to epigenetic reprogramming in the mouse germline. Development (2012) 1.55
Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of cellular fusion. Gastroenterology (2003) 1.55
Redistribution of H3K27me3 upon DNA hypomethylation results in de-repression of Polycomb target genes. Genome Biol (2013) 1.47
DNA methylation reprogramming in cancer: does it act by re-configuring the binding landscape of Polycomb repressive complexes? Bioessays (2013) 1.45
Kaiso is a genome-wide repressor of transcription that is essential for amphibian development. Development (2004) 1.41
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res (2010) 1.37
Senescent cells harbour features of the cancer epigenome. Nat Cell Biol (2013) 1.34
Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer (2005) 1.33
Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res (2007) 1.31
WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res (2009) 1.25
While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. Mol Cell Biol (2003) 1.24
Expression of Sonic hedgehog pathway genes is altered in colonic neoplasia. J Pathol (2004) 1.24
Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One (2013) 1.21
Non-canonical functions of the DNA methylome in gene regulation. Biochem J (2013) 1.21
DNA methylation at promoter regions regulates the timing of gene activation in Xenopus laevis embryos. Dev Biol (2002) 1.20
A determining influence for CpG dinucleotides on nucleosome positioning in vitro. Nucleic Acids Res (2004) 1.19
Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol (2012) 1.19
Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. J Pathol (2003) 1.17
Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans. PLoS One (2009) 1.16
Hematopoietic stem cell trafficking in liver injury. FASEB J (2005) 1.16
What can molecular pathology contribute to the management of renal cell carcinoma? Nat Rev Urol (2011) 1.15
TNF-alpha induced DNA damage in primary murine hepatocytes. Int J Mol Med (2003) 1.15
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res (2006) 1.14
Prognostic relevance of DNA copy number changes in colorectal cancer. J Pathol (2010) 1.14
Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol (2009) 1.14
The effect of interspecific oocytes on demethylation of sperm DNA. Proc Natl Acad Sci U S A (2004) 1.14
Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer (2011) 1.13
Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression. Nucleic Acids Res (2012) 1.12
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One (2013) 1.12
Genomic insights into cancer-associated aberrant CpG island hypermethylation. Brief Funct Genomics (2013) 1.11
xDnmt1 regulates transcriptional silencing in pre-MBT Xenopus embryos independently of its catalytic function. Development (2008) 1.11
Specific nuclear envelope transmembrane proteins can promote the location of chromosomes to and from the nuclear periphery. Genome Biol (2013) 1.11
Reduced levels of two modifiers of epigenetic gene silencing, Dnmt3a and Trim28, cause increased phenotypic noise. Genome Biol (2010) 1.10
The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers. Mol Cell Biol (2010) 1.10
A further survey of surgical management of the axilla in UK breast cancer patients. Ann R Coll Surg Engl (2010) 1.09
Non-genotoxic carcinogen exposure induces defined changes in the 5-hydroxymethylome. Genome Biol (2012) 1.09
The interaction of xKaiso with xTcf3: a revised model for integration of epigenetic and Wnt signalling pathways. Development (2009) 1.09
New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev (2012) 1.08
Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm (2013) 1.08
Dynamic changes in 5-hydroxymethylation signatures underpin early and late events in drug exposed liver. Nucleic Acids Res (2013) 1.07
The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes (2009) 1.07
Systems pathology--taking molecular pathology into a new dimension. Nat Rev Clin Oncol (2009) 1.06
Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. J Med Econ (2013) 1.05
Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. PLoS One (2011) 1.05
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res (2013) 1.04
Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles. BMC Genomics (2010) 1.04
Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget (2012) 1.04
An unbalanced maternal diet in pregnancy associates with offspring epigenetic changes in genes controlling glucocorticoid action and foetal growth. Clin Endocrinol (Oxf) (2012) 1.04
ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol (2005) 1.03
Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol (2010) 1.02
Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res (2008) 1.02
Microarray analysis of LTR retrotransposon silencing identifies Hdac1 as a regulator of retrotransposon expression in mouse embryonic stem cells. PLoS Comput Biol (2012) 1.02
Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor. Cancer Res (2006) 1.01
The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells. PLoS One (2012) 1.00
A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity. Oncotarget (2014) 1.00
Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Res Treat (2010) 1.00
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin Cancer Res (2011) 1.00